Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Pharmacylics

    - PMLiVE

    J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

    The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

    - PMLiVE

    Janssen/Pharmacyclics’ ibrutinib shows continued survival benefit in chronic lymphocytic leukaemia

    The slow-growing blood cancer affects approximately 4.92 per 100,000 people every year in Europe

    - PMLiVE

    Janssen’s Carvykti recommended by CHMP for earlier multiple myeloma treatment

    The blood cancer affects approximately 160,000 people worldwide

    - PMLiVE

    Janssen reveals positive results for nipocalimab in rheumatoid arthritis

    About 13 million people worldwide are affected by the chronic inflammatory disease

    - PMLiVE

    Janssen’s Tecvayli approved by EC for reduced dosing frequency in multiple myeloma

    Tecvayli was the first BCMA-targeting bispecific antibody to be approved in Europe

    - PMLiVE

    Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer

    The therapy showed an overall response rate of more than 70% in a broad range of patients

    - PMLiVE

    Janssen receives positive CHMP opinion for Talvey in multiple myeloma

    More than 50,900 people in Europe were diagnosed with multiple myeloma in 2020

    - PMLiVE

    Johnson & Johnson sues US government over Medicare drug price negotiation programme

    The IRA allows Medicare to negotiate lower prices for a selected group of medicines

    - PMLiVE

    Janssen signs $2.5bn deal with Nanobiotix for late-stage radiotherapy enhancer

    The agreement marks a significant boost to the Johnson & Johnson unit’s oncology pipeline

    - PMLiVE

    Janssen announces positive phase 2b results for JNJ-2113 in plaque psoriasis

    The immune-mediated disease is estimated to affect more than 125 million people worldwide

    - PMLiVE

    AbbVie files patent infringement lawsuit against BeiGene’s blood cancer drug Brukinsa

    The BTK inhibitor was approved in the US earlier this year and had its patent issued last week

    - PMLiVE

    Janssen shares positive phase 3 results for cilta-cel in multiple myeloma

    An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links